Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNPH1 | O43598 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 5/20 | 0.41 |
| ▸ | RIN1 | Q13671 | 5/20 | 0.41 |
| ▸ | NR2F2 | P24468 | 3/20 | 0.40 |
| ▸ | GALR3 | O60755 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALB | P02768 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12566427 | 0.85 | DNPH1 (0.47) | DNPH1CYP1A2ABL1RIN1NR2F2 | |
| SCHEMBL21562373 | 0.81 | ALDH1A1 (0.55) | DNPH1CYP1A2ABL1RIN1NR2F2 | |
| SCHEMBL12652510 | 0.78 | DNPH1 (0.64) | DNPH1 | |
| SCHEMBL20008060 | 0.77 | NR2F2 (0.54) | NR2F2ALDH1A1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL12566441 | 0.75 | BCHE (0.43) | DNPH1CYP1A2BCHE | |
| SCHEMBL12652416 | 0.75 | DNPH1 (0.43) | DNPH1CYP1A2BCHE | |
| SCHEMBL21392957 | 0.75 | BLM (0.55) | CYP1A2ALDH1A1LMNAALBMAPK1 | |
| SCHEMBL22907485 | 0.73 | CYP1A2 (0.43) | CYP1A2ABL1RIN1NR2F2GALR3 | |
| SCHEMBL12566844 | 0.73 | BCHE (0.44) | DNPH1CYP1A2ALDH1A1LMNAALB | |
| SCHEMBL12566802 | 0.73 | BCHE (0.44) | DNPH1CYP1A2ALDH1A1LMNAALB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136834-A1 | INHIBITORS OF E1 ACTIVATING ENZYMES | ECE1, RNASE1, RCE1 | DNPH1 336/4885CYP1A2 644/4885ABL1 2833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.